靶向 CD19 CAR-T 细胞治疗的非 ICANS 神经毒性与运动及神经认知治疗中出现的不良事件:一例病例报告 Non-ICANS neurotoxicities CD19-directed CAR T-cell therapy and the emergence of movement and neurocognitive treatment-emergent adverse events: a case PubMed 2026/02/16 发表Front ImmunolQ1 · IF 7(JCR 2025) 靶点:CD19靶点:CD38靶点:BCMA技术:CAR-T弥漫大B细胞淋巴瘤多发性骨髓瘤淋巴瘤
肾脏病学趋势:从虚无主义到抗体介导排斥反应的靶向治疗 Trends in Nephrology: From nihilism to targeted treatment of antibody-mediated rejection. PubMed 2026/01/24 发表Nephrol Dial TransplantQ1 · IF 8.3(JCR 2025) 靶点:CD19靶点:CD20靶点:CD38技术:NK 细胞技术:双特异性抗体多发性骨髓瘤
多发性骨髓瘤的细胞治疗:现状与未来 Cellular therapy for multiple myeloma: what's now and what's next. PubMed 2022/12/09 发表Hematology Am Soc Hematol Educ ProgramQ1 · IF 3.7(JCR 2025) 靶点:CD19靶点:CD38靶点:BCMA技术:CAR-T技术:双特异性抗体多发性骨髓瘤
CAR 与嵌合共刺激受体联用增强 T 细胞对低抗原密度的敏感性并促进持久性 Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. PubMed 2021/12/08 发表Sci Transl MedQ1 · IF 15.6(JCR 2025) 靶点:CD19靶点:CD38靶点:BCMA技术:CAR-T急性淋巴细胞白血病多发性骨髓瘤